F
Feops
Cutting-edge technology that creates digital twins from cardiac scans
About Feops
Developer of a cardiac imaging technology designed to improve and expand personalized treatment for patients with structural heart disease. The company offers AI-enabled anatomical analyses to generate data-driven insights to improve transcatheter valve procedures based on personalized computer simulations, enabling healthcare professionals to improve both procedure efficiency and clinical outcomes. Keywords: Pharmaceuticals and Biotechnology, Cardiovascular Intervention, Computer Simulation, Invasive Device, Patient-Specific Insights, Structural Heart Intervention, Transcatheter Heart Valve, Transcatheter Valves System.
Source: Dealroom company dataAt a glance
- Founded
- 2009
- Headquarters
- Ghent, Belgium
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
European Innovation Council
Series A5 investors entered at this stage
Capricorn Partners
28DIGITAL Accelerator
Valiance Asset Management
PMV- VIValiance Life Science Investments
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Feops on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Feops on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.